Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBERT M CARLILE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1740575307
CMS profile
1388697
Location
SUMMERVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$103,362.24

423 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $50,422.04 66
ABBVIE INC. $22,818.74 50
C2N Diagnostics, LLC $13,680.84 20
Teva Pharmaceuticals USA, Inc. $11,313.70 23
ACADIA Pharmaceuticals Inc $826.61 33
TG Therapeutics, Inc. $426.78 20
UCB, Inc. $360.83 22
EMD Serono, Inc. $339.62 10
PFIZER INC. $286.83 25
Lundbeck LLC $235.10 16
Supernus Pharmaceuticals, Inc. $208.77 10
Axsome Therapeutics, Inc. $203.36 17
Novartis Pharmaceuticals Corporation $191.61 16
Amgen Inc. $186.54 12
Biogen, Inc. $178.32 12
ARGENX US, INC. $127.64 6
Sumitomo Pharma America, Inc. $118.57 4
Alexion Pharmaceuticals, Inc. $118.34 4
GENZYME CORPORATION $117.76 5
Neurocrine BioSciences, Inc. $94.80 4
F. Hoffmann-La Roche AG $80.00 1
Celgene Corporation $79.52 4
CSL Behring $79.02 3
Averitas Pharma Inc. $72.39 2
Merz Pharmaceuticals, LLC $66.94 3
Otsuka America Pharmaceutical, Inc. $60.30 3
Eisai Inc. $56.28 2
Vanda Pharmaceuticals Inc. $54.93 3
AstraZeneca Pharmaceuticals LP $44.66 2
MDD US Operations, LLC $44.27 3
CATALYST PHARMACEUTICALS, INC. $43.80 2
Amneal Pharmaceuticals LLC $42.03 2
Grifols USA, LLC $35.65 2
E.R. Squibb & Sons, L.L.C. $34.48 1
Takeda Pharmaceuticals U.S.A., Inc. $29.13 1
ANI Pharmaceuticals, Inc. $28.47 1
Ultragenyx Pharmaceutical Inc. $26.50 1
Eli Lilly Export S.A. Puerto Rico Branch $25.00 1
Neurelis, Inc. $24.72 1
Mallinckrodt Hospital Products Inc. $22.63 1
Sonex Health, Inc. $21.25 1
InSightec,Inc $19.08 1
Tanabe Pharma America, Inc. $18.17 1
Genentech USA, Inc. $17.76 1
SpringWorks Therapeutics, Inc. $17.15 1
Alnylam Pharmaceuticals Inc. $16.94 1
Medtronic, Inc. $15.56 1
Xeris Pharmaceuticals, Inc. $14.91 1
JAZZ PHARMACEUTICALS INC. $13.90 1

Page 7 of 9; records 301–350 of 423 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBERT M CARLILE

NPI 1740575307 · CMS profile ID 1388697

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

SUMMERVILLE, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 7 of 9; records 301–350 of 423 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740575307?year=2025&recipient=provider&page=7#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBERT M CARLILE, NPI 1740575307, CMS profile ID 1388697. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 423 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740575307?year=2025&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). ROBERT M CARLILE, NPI 1740575307, CMS profile ID 1388697. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 423 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740575307?year=2025&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
ROBERT M CARLILE, NPI 1740575307, CMS profile ID 1388697, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 9; records 301–350 of 423 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1740575307?year=2025&recipient=provider&page=7#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

423 matching records · $103,362.24 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 423 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 301–350 of 423.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $6.8904/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228818893 CMS
ABBVIE INC. $17.6204/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201607611 CMS
Lilly USA, LLC $800.0004/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186892983 CMS
Medtronic, Inc. $15.5604/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1219028403 CMS
TG Therapeutics, Inc. $21.7104/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226267994 CMS
ABBVIE INC. $3,675.0004/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201607609 CMS
Lilly USA, LLC $800.0004/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186865057 CMS
EMD Serono, Inc. $119.6804/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236924506 CMS
Lundbeck LLC $20.5004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251781742 CMS
Teva Pharmaceuticals USA, Inc. $8.7304/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247325819 CMS
ARGENX US, INC. $21.1304/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1240445023 CMS
Alnylam Pharmaceuticals Inc. $16.9404/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212737089 CMS
Lilly USA, LLC $14.6604/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186853515 CMS
Lilly USA, LLC $800.0004/09/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186884067 CMS
PFIZER INC. $8.7404/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228861973 CMS
Biogen, Inc. $22.9704/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208435055 CMS
ABBVIE INC. $1,575.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201607607 CMS
ACADIA Pharmaceuticals Inc $34.9904/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247769033 CMS
UCB, Inc. $6.3304/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224478966 CMS
Teva Pharmaceuticals USA, Inc. $4,830.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247325687 CMS
Novartis Pharmaceuticals Corporation $6.9704/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200007527 CMS
Lilly USA, LLC $800.0003/31/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186914784 CMS
Lundbeck LLC $8.2903/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251781740 CMS
UCB, Inc. $26.5603/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224478964 CMS
ACADIA Pharmaceuticals Inc $7.7203/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247769031 CMS
TG Therapeutics, Inc. $26.4403/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226267980 CMS
ABBVIE INC. $15.3903/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201607605 CMS
AstraZeneca Pharmaceuticals LP $22.7403/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1206737576 CMS
Lilly USA, LLC $800.0003/26/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186865055 CMS
Neurocrine BioSciences, Inc. $16.1903/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1243039697 CMS
Novartis Pharmaceuticals Corporation $7.8303/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200007513 CMS
Lilly USA, LLC $7.1303/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186930920 CMS
UCB, Inc. $14.3403/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224478962 CMS
ABBVIE INC. $107.6503/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201607601 CMS
ABBVIE INC. $1,154.4703/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1201607603 CMS
Teva Pharmaceuticals USA, Inc. $7.6203/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247325799 CMS
ABBVIE INC. $0.0303/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201607599 CMS
PFIZER INC. $7.1103/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1231275123 CMS
ABBVIE INC. $2,625.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201607593 CMS
ABBVIE INC. $4.8003/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201607595 CMS
ABBVIE INC. $3,675.0003/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1201607597 CMS
EMD Serono, Inc. $19.5903/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1236902310 CMS
ACADIA Pharmaceuticals Inc $8.5703/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247769029 CMS
TG Therapeutics, Inc. $21.6603/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226267986 CMS
ABBVIE INC. $21.5303/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201607591 CMS
Biogen, Inc. $10.9403/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208483216 CMS
Teva Pharmaceuticals USA, Inc. $1,115.4003/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1247325595 CMS
Teva Pharmaceuticals USA, Inc. $3,570.0003/12/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247325597 CMS
Teva Pharmaceuticals USA, Inc. $112.6603/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247325781 CMS
CSL Behring $25.4703/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1232369052 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $40,435.50 304
PY2020 $44,736.97 298
PY2021 $57,564.92 357
PY2022 $70,447.69 419
PY2023 $36,265.02 392
PY2024 $74,712.56 371
PY2025 $103,362.24 423

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $5,580.49 1
PY2025 Principal investigator $896,196.66 33
PY2024 Recipient $7,308.40 3
PY2024 Principal investigator $610,642.92 32
PY2023 Recipient $168.48 1
PY2023 Principal investigator $339,401.85 17
PY2022 Principal investigator $53,346.98 5
PY2021 Principal investigator $2,223.80 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

34 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $300.00 11/20/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213742933
Principal investigator 1 Novo Nordisk AS $2,500.00 11/20/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213743597
Principal investigator 1 Novo Nordisk AS $2,000.00 11/20/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213777319
Principal investigator 1 Novo Nordisk AS $3,673.41 10/29/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213792738
Principal investigator 1 Eli Lilly and Company $1,019.58 10/27/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH LOW COUNTRY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888316
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,727.00 10/17/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068337
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $202.00 10/17/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068339
Principal investigator 1 Genentech, Inc. $17,600.00 10/16/2025 Non-covered Recipient Entity
Palmetto Clinical Research Low Country
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211636195
Principal investigator 1 Genentech, Inc. $21,989.00 10/15/2025 Non-covered Recipient Entity
Palmetto Clinical Research Low Country
Alzheimer's Disease Master Pre Screener No dispute reported 06/30/2026 1211636199
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $2,547.70 10/15/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068335
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $7,000.00 10/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068331
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,609.00 10/08/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068333
Principal investigator 1 Amgen Inc. $2,000.00 08/23/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246649433
Principal investigator 1 Novo Nordisk AS $2,500.00 08/18/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213847929
Principal investigator 1 Novo Nordisk AS $1,021.25 07/16/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213778368
Principal investigator 1 ABBVIE INC. $5,961.60 06/04/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202490163
Principal investigator 1 ABBVIE INC. $15,994.80 05/07/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 2, Randomised, Multicentre, Parallel-Group Treatment, Double-Blind Study to Investigate the Safety and Efficacy of Subcutaneous MEDI0618 in the Reduction of Migraine Headache Days Compared to Placebo in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202484161
Principal investigator 1 AstraZeneca UK Limited $17,983.60 05/07/2025 Non-covered Recipient Entity
GREAT LAKES PHARMACY
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185547349
Principal investigator 1 Amgen Inc. $21,048.25 04/24/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246649426
Principal investigator 1 Novo Nordisk AS $2,367.40 04/21/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213754518
Principal investigator 1 Eli Lilly and Company $84,611.00 04/08/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH LOW COUNTRY
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187888426
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $378.00 03/19/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068111
Principal investigator 1 Novartis Pharmaceuticals Corporation $294,506.16 03/17/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190306487
Principal investigator 1 AstraZeneca UK Limited $59,484.30 03/05/2025 Non-covered Recipient Entity
THE CLINICAL TRIALS NETWORK
a phase 2,randomised,multicentre, parallel group treatment,double blind study to investigate the safety and efficacy of subcutaneous MEDI0618 in the reduction of migraine headache days compared to placebo in adult participants with episodic migraine No dispute reported 06/30/2026 1185547347
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $480.00 03/05/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248068109
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $1,364.20 02/19/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067869
Principal investigator 1 Novo Nordisk AS $1,021.25 01/31/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
NN6535-4725 No dispute reported 06/30/2026 1213810280
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $12,557.10 01/29/2025 Non-covered Recipient Entity
The Clinical Trials Network LLC
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066873
Recipient Eli Lilly and Company $5,580.49 01/27/2025 Covered Recipient Physician A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187871425
Principal investigator 1 Eli Lilly and Company $12,443.00 01/27/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH LOW COUNTRY
EVALUATION OF THE LILLY SP-X P-TAU217 ASSAY BY MEASURING CHANGES IN THE INTENDED PATIENT MANAGEMENT BETWEEN PRE-AND POST-P-TAU217 RESULT: A RANDOMIZED CLINICAL UTILITY STUDY No dispute reported 06/30/2026 1187887492
Principal investigator 1 Novartis Pharmaceuticals Corporation $61,797.81 01/16/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311815
Principal investigator 1 Amgen Inc. $3,434.91 01/09/2025 Non-covered Recipient Entity
PALMETTO GASTROENTEROLOGY CLINICAL RESEARCH, LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Episodic Migraine (OASIS PEDIATRIC [EM]) No dispute reported 06/30/2026 1246646290
Principal investigator 1 Novartis Pharmaceuticals Corporation $215,155.95 01/07/2025 Non-covered Recipient Entity
PALMETTO CLINICAL RESEARCH
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190306485
Principal investigator 1 Amgen Inc. $16,918.39 01/02/2025 Non-covered Recipient Entity
PALMETTO GASTROENTEROLOGY CLINICAL RESEARCH, LLC
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM]) No dispute reported 06/30/2026 1246646286